53 related articles for article (PubMed ID: 14670125)
1. Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.
Hwang KS; Cho WK; Yoo J; Yun HJ; Kim S; Im DS
BMC Cancer; 2005 May; 5():51. PubMed ID: 15910693
[TBL] [Abstract][Full Text] [Related]
2. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
Eguchi J; Hiroishi K; Ishii S; Mitamura K
Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
[TBL] [Abstract][Full Text] [Related]
3. Construction of a single-chain interleukin-12-expressing retroviral vector and its application in cytokine gene therapy against experimental coccidioidomycosis.
Jiang C; Magee DM; Cox RA
Infect Immun; 1999 Jun; 67(6):2996-3001. PubMed ID: 10338510
[TBL] [Abstract][Full Text] [Related]
4. Suppression of in vivo tumor growth by the transfection of the interleukin-5 gene into colon tumor cells.
Masuda Y; Mita S; Sakamoto K; Ishiko T; Ogawa M
Cancer Immunol Immunother; 1995 Dec; 41(6):325-30. PubMed ID: 8635189
[TBL] [Abstract][Full Text] [Related]
5. NK cells are migrated and indispensable in the anti-tumor activity induced by CCL27 gene therapy.
Gao JQ; Tsuda Y; Han M; Xu DH; Kanagawa N; Hatanaka Y; Tani Y; Mizuguchi H; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
Cancer Immunol Immunother; 2009 Feb; 58(2):291-9. PubMed ID: 18629495
[TBL] [Abstract][Full Text] [Related]
6. huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models.
Lo KM; Lan Y; Lauder S; Zhang J; Brunkhorst B; Qin G; Verma R; Courtenay-Luck N; Gillies SD
Cancer Immunol Immunother; 2007 Apr; 56(4):447-57. PubMed ID: 16874486
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.
Smallridge RC; Copland JA
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):486-97. PubMed ID: 20418080
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model.
Jarnagin WR; Delman K; Kooby D; Mastorides S; Zager J; Brennan MF; Blumgart LH; Federoff H; Fong Y
Ann Surg; 2000 May; 231(5):762-71. PubMed ID: 10767798
[TBL] [Abstract][Full Text] [Related]
9. Uric acid accumulation in DNA-damaged tumor cells induces NKG2D ligand expression and antitumor immunity by activating TGF-β-activated kinase 1.
Wang J; Liu K; Xiao T; Liu P; Prinz RA; Xu X
Oncoimmunology; 2022; 11(1):2016159. PubMed ID: 35154904
[TBL] [Abstract][Full Text] [Related]
10. Immune Landscape of Thyroid Cancers: New Insights.
Menicali E; Guzzetti M; Morelli S; Moretti S; Puxeddu E
Front Endocrinol (Lausanne); 2020; 11():637826. PubMed ID: 33986723
[TBL] [Abstract][Full Text] [Related]
11. Interleukins in Thyroid Cancer: From Basic Researches to Applications in Clinical Practice.
Xi C; Zhang GQ; Sun ZK; Song HJ; Shen CT; Chen XY; Sun JW; Qiu ZL; Luo QY
Front Immunol; 2020; 11():1124. PubMed ID: 32655554
[TBL] [Abstract][Full Text] [Related]
12. Immune Microenvironment of Thyroid Cancer.
Yin H; Tang Y; Guo Y; Wen S
J Cancer; 2020; 11(16):4884-4896. PubMed ID: 32626535
[TBL] [Abstract][Full Text] [Related]
13. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.
Varricchi G; Loffredo S; Marone G; Modestino L; Fallahi P; Ferrari SM; de Paulis A; Antonelli A; Galdiero MR
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412566
[TBL] [Abstract][Full Text] [Related]
14. Xanthine oxidoreductase is required for genotoxic stress-induced NKG2D ligand expression and gemcitabine-mediated antitumor activity.
Xu X; Rao G; Li Y
Oncotarget; 2016 Sep; 7(37):59220-59235. PubMed ID: 27494876
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic thyroid carcinoma: a therapeutic dilemma.
Chang HS; Nam KH; Chung WY; Park CS
Yonsei Med J; 2005 Dec; 46(6):759-64. PubMed ID: 16385650
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy of anaplastic thyroid carcinoma with a single-chain interleukin-12 fusion protein.
Shi Y; Parhar RS; Zou M; Baitei E; Kessie G; Farid NR; Alzahrani A; Al-Mohanna FA
Hum Gene Ther; 2003 Dec; 14(18):1741-51. PubMed ID: 14670125
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma.
Shi Y; Zou M; Baitei EY; Alzahrani AS; Parhar RS; Al-Makhalafi Z; Al-Mohanna FA
Cancer Gene Ther; 2008 Feb; 15(2):101-7. PubMed ID: 18197164
[TBL] [Abstract][Full Text] [Related]
18. IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model.
Parhar RS; Zou M; Al-Mohanna FA; Baitei EY; Assiri AM; Meyer BF; Shi Y
Lab Invest; 2016 Jan; 96(1):89-97. PubMed ID: 26501867
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
